Group 1 - The board of directors of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. held its fourth meeting of the sixth session on August 15, 2025, with all nine directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the annual report and its summary, with detailed content available on the company's disclosure platform [1][2] - The board also approved a special report on the use of raised funds, which was reviewed by the audit committee [2][3] Group 2 - The board authorized the core management team to handle changes related to the raised funds account, including the cancellation and opening of accounts [3] - A temporary shareholders' meeting is scheduled for September 15, 2025, to discuss various proposals, including changes to the company's registered capital and amendments to the articles of association [2][3] - The company aims to improve the efficiency of fund usage by transferring the balance of raised funds to a different bank account [2][3]
华兰股份: 董事会决议公告